返回 
加入收藏
仙灵骨葆胶囊用于膝骨关节炎的系统评价再评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 仙灵骨葆胶囊用于膝骨关节炎的系统评价再评价 |
| TITLE： | Reevaluation of systematic evluation of Xianling gubao capsules for knee osteoarthritis |
| 摘要： | 目的 对仙灵骨葆胶囊用于膝骨关节炎（KOA）的系统评价（SR）/Meta分析进行系统评价再评价，以期为该药的临床应用提供循证支持。方法检索中国知网、万方数据、维普网、中国生物医学文献数据库、theCochraneLibrary、PubMed、Embase和WebofScience，收集仙灵骨葆胶囊用于KOA有效性及安全性的SR/Meta分析，检索时限为建库至2024年5月31日。通过PRISMA2020声明、AMSTAR2量表、ROBIS工具和GRADE工具分别进行报告质量、方法学质量、偏倚风险和证据质量评价，同时对SR/Meta分析的定量结果进行综合质量分析。结果共纳入5篇SR/Meta分析。PRISMA2020声明评价结果显示，1项研究的信息相对完整（21分），4项研究存在信息缺陷（18～20分）；AMSTAR2量表评价结果显示，5项研究的方法学质量均为极低级；ROBIS工具评价结果显示，5项研究的综合偏倚风险程度为“高风险”；GRADE工具评价结果显示，49个结局指标中，含中级证据5个（10.2%）、低级证据12个（24.5%）、极低级证据32个（65.3%）。综合质量分析结果显示，仙灵骨葆胶囊联合常规治疗者的临床有效率、视觉模拟评分法评分、疼痛缓解时间、膝关节功能综合指标、炎症因子水平及不良反应发生率均显著优于常规治疗者（P＜0.05）。结论与常规治疗相比，仙灵骨葆胶囊联合常规治疗用于KOA可能具有一定的疗效和安全性优势。但由于纳入研究的结局指标证据质量较低，因此所得结论需谨慎解读。 |
| ABSTRACT： | OBJECTIVE To conduct a reevaluation of the systematic review （SR）/meta-analysis on the use of Xianling gubao capsules （XLGBC） for knee osteoarthritis （KOA）， and provide evidence-based support for the clinical use of the drugs. METHODS Computerized searches including CNKI， Wanfang Data， VIP， China Biomedical Literature Database， the Cochrane Library， PubMed， Embase and Web of Science were conducted to collect systematic reviews （SR） or meta-analyses of XLGBC for the treatment of KOA from the inception to May 31st， 2024. The report quality， methodological quality， risk of bias and evidence quality were assessed using the PRISMA 2020 statement， AMSTAR 2 scale， ROBIS tool and GRADE tool， respectively. A comprehensive quality analysis of the quantitative results from the SR/meta-analysis was also performed. RESULTS A total of five SR/meta-analyses were included. The evaluation results based on the PRISMA 2020 statement showed that one study report was relatively complete （21 points）， while four studies had deficiencies （18-20 points）. The assessment using the AMSTAR 2 scale indicated that the methodological quality of all five studies was rated as very low. According to the ROBIS tool evaluation， the risk of comprehensive bias in all five studies was classified as high. GRADE tool evaluation revealed that among 49 outcome indicators， 5 （10.2%） were rated as moderate-quality evidence （10.2%）， 12 as low-quality evidence （24.5%）， and 32 as very low-quality evidence （65.3%）. The results of comprehensive quality analysis showed that the clinical efficacy， visual analogue scale score， pain relief time， comprehensive indexes of knee joint function， the levels of inflammatory factors and the incidence of adverse events in patients with XLGBC combined with conventional treatment were significantly better than conventional treatment alone （P＜0.05）. CONCLUSIONS Compared with conventional treatment， XLGBC in combination with conventional treatment for KOA may have some efficacy and safety advantages. However， due to the low quality of evidence for the outcome indicators included in the studies， the conclusions should be interpreted with caution. |
| 期刊： | 2025年第36卷第02期 |
| 作者： | 曹东东；陈继鑫；余伟杰；郭天赐；张宇；牛朴钰；刘爱峰 |
| AUTHORS： | CAO Dongdong，CHEN Jixin，YU Weijie，GUO Tianci，ZHANG Yu，NIU Puyu，LIU Aifeng |
| 关键字： | 仙灵骨葆胶囊；膝骨关节炎；疗效；安全性；系统评价再评价 |
| KEYWORDS： | Xianling gubao capsules； knee osteoarthritis； efficacy； safety； reevaluation of systematic review |
| 阅读数： | 21 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
